Supportive therapies and neutrophil recovery after ide-cel CAR-T therapy
| Characteristic . | Value, N = 52 . |
|---|---|
| Granulocyte colony stimulating factor (G-CSF) – n (%) | 46 (88%) |
| First day of G-CSF – median (range) | 9 (1–93) |
| Last day of G-CSF – median (range) | 28.5 (6–100) |
| CD34+stem cell boost– n (%) | 4 (8%) |
| Day of CD34+ stem cell boost – median (range) | 54 (53–76) |
| Dose of stem cell boost (CD34+ cells × 106/kg) – median (range) | 3.12 (1.82–7.38) |
| Day of neutrophil recovery – median (range) | 30 (7–94) |
| ANC never fell below 500 cells/μL – n (%) | 5 (10%) |
| Did not recover neutrophils prior to death, PD, or day 100 – n (%) | 6 (12%) |
| Transfusion post-CAR T – n (%) | 34 (65%) |
| pRBC transfusion within 7 days | 27 (52%) |
| Platelet transfusion within 7 days | 15 (29%) |
| pRBC transfusion > 7 days | 24 (46%) |
| Platelet transfusion > 7 days | 22 (42%) |
| Thrombopoietin (TPO) agonist – n (%) | 11 (21%) |
| First day of TPO agonist – median (range) | 35 (23–63) |
| Last day of TPO agonist – median (range) | 100 (44–100) |
| Intravenous immunoglobulin (IVIG) – n (%) | 7 (13%) |
| First day of IVIG – median (range) | 39 (25–99) |
| Last day of IVIG – median (range) | 100 (25–100) |
| Characteristic . | Value, N = 52 . |
|---|---|
| Granulocyte colony stimulating factor (G-CSF) – n (%) | 46 (88%) |
| First day of G-CSF – median (range) | 9 (1–93) |
| Last day of G-CSF – median (range) | 28.5 (6–100) |
| CD34+stem cell boost– n (%) | 4 (8%) |
| Day of CD34+ stem cell boost – median (range) | 54 (53–76) |
| Dose of stem cell boost (CD34+ cells × 106/kg) – median (range) | 3.12 (1.82–7.38) |
| Day of neutrophil recovery – median (range) | 30 (7–94) |
| ANC never fell below 500 cells/μL – n (%) | 5 (10%) |
| Did not recover neutrophils prior to death, PD, or day 100 – n (%) | 6 (12%) |
| Transfusion post-CAR T – n (%) | 34 (65%) |
| pRBC transfusion within 7 days | 27 (52%) |
| Platelet transfusion within 7 days | 15 (29%) |
| pRBC transfusion > 7 days | 24 (46%) |
| Platelet transfusion > 7 days | 22 (42%) |
| Thrombopoietin (TPO) agonist – n (%) | 11 (21%) |
| First day of TPO agonist – median (range) | 35 (23–63) |
| Last day of TPO agonist – median (range) | 100 (44–100) |
| Intravenous immunoglobulin (IVIG) – n (%) | 7 (13%) |
| First day of IVIG – median (range) | 39 (25–99) |
| Last day of IVIG – median (range) | 100 (25–100) |
If the exact day of supportive therapy initiation or discontinuation was unknown due to administration outside of the institution, day of first or last documentation of use in the medical record was used as a surrogate. Data were censored at day 100, and so day 100 is given as last day of use if therapy was ongoing. Neutrophil recovery was defined as first day of ANC (absolute neutrophil count) > 500 cells/μL sustained on 2 consecutive checks without G-CSF use in the prior 7 days. Median and range of neutrophil recovery reflects data for the 41 patients whose ANC fell below 500 cells/μL after idecabtagene vicleucel (ide-cel) infusion and recovered prior to day 100 in the absence of death or progression. PD, progressive disease; pRBC, packed red blood cell.